Core Insights - The weight loss drug market is experiencing significant volatility, particularly affecting Novo Nordisk and Hims & Hers, with Novo's stock rising nearly 5% while Hims & Hers fell over 26% following the latter's decision to withdraw its generic Wegovy pill [2][10]. Company Developments - Hims & Hers announced it would pull its compounded semaglutide pill, a copycat version of Novo Nordisk's Wegovy, after facing potential legal action from Novo [3][4]. - The compounded pill was initially offered at $49, approximately $100 less than Novo's pricing, which raised questions about its market viability [4]. - Novo Nordisk has increased its manufacturing capabilities, including a $16 billion acquisition of a manufacturer, effectively addressing supply shortages that previously allowed Hims & Hers to enter the market [6]. Regulatory Environment - The FDA is taking decisive steps to restrict practices by compounding pharmacies that market non-FDA-approved drugs as comparable to approved medications, which could further impact Hims & Hers [7][9]. - Analysts from Citi and B of A have lowered their price targets for Hims & Hers, reflecting concerns over legal risks and market competition, with Citi reducing its target from $30 to $16.50 and B of A from $26 to $21 [8][9]. Market Implications - The exit of Hims & Hers from the market is seen as a positive development for Novo Nordisk and Eli Lilly, as reduced competition in the GLP-1 weight loss space benefits these companies [10]. - The overall market sentiment remains cautious, with volatility affecting trading strategies, particularly for Hims & Hers, which is expected to face continued downward pressure [12][15].